Visoluten
A-11, retina peptide bioregulator
Visoluten is a retina-derived peptide complex, listed as A-11. It is the only compound in this cohort whose target organ has no blood test at all, which turns out to be the most interesting thing about it: every honest endpoint for this product is an eye measurement, all of them are standardized and quantitative, and 0 of them have ever been published for it. This page says what those measurements are and why the blood work below is a supporting cast rather than the answer.
Visoluten quick facts
| Reported research dose | 40-160mg daily (1-2 capsules, 1-2x daily with food · 40mg/capsule) |
| Route | Oral |
| Frequency | 1-2x Daily · Daily during a course |
| Half-life | Not characterized |
| Forms | Oral |
| Evidence level | Theoretical — Khavinson-school work, largely Russian-language and rarely replicated outside it |
The Khavinson literature behind this is decades deep, almost entirely Russian-language, and rarely replicated by any independent group — small single-arm series rather than controlled trials. Absence of replication is not evidence it fails; it is an absence of the evidence that would settle it either way. Dose and course length follow the manufacturer's convention, not a trial. Retina-directed. A narrow target and an unusual one, which is both the appeal and the reason there is so little to go on. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, an actual eye exam with a measured acuity — not a self-assessment. Run it as an experiment you measure, not a protocol you trust.
What Visoluten actually is — and why that changes the mechanism
Visoluten is a retina-derived peptide complex in capsules, listed as A-11. It is the only compound in this cohort whose target organ has no blood test, and rather than being a problem for the page that turns out to be the most useful fact on it.
What that means in practice. Every other product in this cohort can be argued about using markers a reader can order: PTH and calcium, testosterone and LH, ferritin and B12. The retina has none. What it has instead is a set of direct measurements that are quantitative, standardized and better than any blood test — visual acuity on a letter chart, retinal thickness in microns on optical coherence tomography, a visual field, and contrast sensitivity. Those are the endpoints. 0 of them have been published for this product in the 5 years since the 2021 review that graded this class, and no blood marker below is a substitute for any of them.
The delivery problem is the sharpest in the cohort, and it has a control condition. The retina sits behind the blood-retinal barrier, a tight-junction barrier whose function is to exclude circulating molecules. A swallowed peptide would have to cross the gut wall — where the class's own named route, PEPT1, carries di- and tripeptides of 2 and 3 residues and not complexes — and then cross that second barrier. 2 barriers in series, 0 papers addressing either for a retinal target. The control condition is how real retinal medicine is delivered: the drugs that work for macular disease are injected directly into the eye, and they are given that way because systemic dosing does not reliably reach the retina. An entire specialty accepts an intraocular injection rather than a tablet, which tells you what the barrier is worth: an injection into the vitreous skips the gut wall, hepatic first-pass extraction and the blood-retinal barrier in 1 step.
What the complex itself commits to. A 2-residue peptide has 400 possible identities, a 4-residue one 160,000, and 'peptide complex' selects none. The nearest structural argument available is the review of the defined tripeptide Glu-Asp-Arg in neural tissue — the retina is neural tissue, which is the only reason it is relevant — and that is an argument about a different molecule in a different place.
What the primary literature on Visoluten actually says
Peptide Regulation of Gene Expression: A Systematic Review
Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR · Molecules 2021;26(22):7053 · PMID 34834147
The 2021 gene-expression review. It is the class's mechanism paper and it is indexed by peptide sequence, with 98 genes credited to AEDG and 36 to Lys-Glu. There is no retinal entry. Whatever this capsule contains has not been characterized well enough to appear in a table keyed on sequence.
EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease
Khavinson V, Linkova N, Kozhevnikova E, Trofimova S · Molecules 2021;26(1):159 · PMID 33396470
The EDR review, cited as the closest structural analogy available. It is about a defined tripeptide, Glu-Asp-Arg, and proposes gene-expression and protein-synthesis mechanisms in neural tissue. The retina is neural tissue, which is the only reason this is on the page — it is an argument by adjacency about a different molecule, not evidence about this product.
The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis
Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
The 2021 independent systematic review — 24 randomized trials, 2,245 participants, risk of bias moderate to high, certainty of evidence low to very low. Cognitive endpoints, and the only outside grading this class has received.
What is not here. Nothing is indexed under the trade name Visoluten. No visual acuity, visual field or retinal imaging endpoint has been published for a retina-derived peptide preparation — which matters, because those are the only endpoints that could settle it and none of them is a blood test. Searched through Europe PMC, PubMed and Google Scholar on 2 September 2026. Naming the gap is more useful than filling it with a paragraph of hedging.
Why the Visoluten evidence is weak — and what it still showed
Almost every human result in this class comes from one school — Vladimir Khavinson's institute in St Petersburg and the groups around it. That means single-center data, collected by the people who developed the compound, rarely blinded, never pre-registered, and reported across enough endpoints that something was always going to move. Read anything below against that.
Specific to Visoluten. The problem specific to Visoluten is a delivery problem stacked on an evidence problem. The retina sits behind the blood-retinal barrier, a tight-junction barrier built to exclude circulating molecules, and this product is swallowed — so anything in it has to cross the gut wall and then that barrier, and 0 papers in this class address either step for a retinal target. The comparison that makes this concrete is how real retinal drugs are given: directly into the eye, by injection, precisely because systemic delivery does not reach the retina reliably. That is not a rhetorical point, it is the routine practice of an entire specialty.
The count: 0. Nothing is indexed under the trade name Visoluten. 0 visual acuity results, 0 visual field results and 0 retinal imaging results have been published for a retina-derived peptide preparation. Searched through Europe PMC, PubMed and Google Scholar on 2 September 2026.
Why that zero is unusually damning here. Vision is the sense people notice losing, and unlike a transcriptional claim it needs no laboratory to detect. Ophthalmology has spent more than 100 years building quantitative endpoints for exactly that reason, and they are cheap relative to almost anything in clinical research: a letter chart, a field test, an imaging scan reported in microns. A product sold for eye health with 0 published measurements on any of them has not been tested with the easy tools, let alone the hard ones.
What the citations are doing. The 2021 gene-expression review indexes 98 genes against AEDG and 36 against Lys-Glu and has 0 retinal entries. The EDR review is about a defined tripeptide in neural tissue and is included as the nearest structural analogy rather than as evidence. The 2021 independent review pooled 24 randomized trials over 2,245 participants on cognitive endpoints, grading risk of bias moderate to high and certainty of evidence low to very low. None of the 3 is about the eye.
What is actually measured, and what is not. Measured: nothing. Not measured, and every one of them is standard ophthalmic practice: best-corrected visual acuity on a letter chart, retinal thickness in microns on optical coherence tomography, a visual field, contrast sensitivity. Also not measured: composition, oral bioavailability, and whether anything in this class crosses the blood-retinal barrier. Published results of any kind: 0.
Not proven is not the same as disproven. Everything above says the evidence is weak. None of it says the compound does nothing. There is no adequately powered trial that ran and came back null, because outside Russia there is essentially no trial at all — this class is unfunded, not failed. A reader who leaves thinking “disproven” has learned something false, and so has one who leaves thinking “proven”.
Visoluten pharmacokinetics — how much of it actually gets in
'Not characterized' is accurate and 0 measurements exist for this preparation in any species. A mixture has one clearance curve per component, so no single half-life could be right for it.
What can be reasoned, and why the usual reasoning does not rescue this one. A short peptide reaching plasma meets serum aminopeptidases and is cut from its termini within minutes. On most pages in this cohort that is survivable, because a transcriptional signal can outlast the molecule that delivered it. Here the problem is upstream of clearance: it is access. The blood-retinal barrier is built from tight junctions specifically to keep circulating solutes out of neural tissue, and a molecule that never crosses it cannot leave a transcriptional signal behind it.
The oral route adds the first barrier. Gastric acid, pancreatic proteases, then the brush border of the small intestine where PEPT1 carries 2- and 3-residue peptides, then hepatic first-pass extraction. 0 oral bioavailability figures exist for any product in this family; an injection is 100% bioavailable by definition and this product is not sold as one.
Now do the arithmetic the blank was hiding. Compare the oral products in this class against the injectable ones and the oral form carries roughly 29x more material per day, and on the order of 571x more across a full course. Take an injection as fully bioavailable — 100% by definition, no gut wall, no hepatic first-pass — and the implication is direct: for the oral route to deliver comparable systemic exposure, on the order of 0.2% of what is swallowed would have to arrive in the circulation intact. Whether a peptide mixture can manage that has never been measured — not for this product and not for any product in this family. Stating the bound is honest. Claiming the fraction would not be.
What would have to be true for Visoluten to work
The chain, and it is 2 barriers long. (1) The capsule would have to contain active peptides — 0 published assays. (2) A fraction would have to cross the gut wall intact — the named route carries 2- and 3-residue peptides and this is a complex. (3) It would then have to cross the blood-retinal barrier — never demonstrated for anything in this class, and the reason retinal drugs are injected into the eye. (4) It would have to change transcription in retinal cells — never observed. (5) Something visual would have to measurably change — and here the tools are excellent and unused, with 0 published measurements despite a delivery route that avoids first-pass extraction entirely being routine practice.
The endpoints that would settle it are not on the list below. Best-corrected visual acuity on a standardized letter chart, retinal thickness in microns on optical coherence tomography, and a visual field, all before and after. Those are the real tests. The blood markers in the predictions are there because they are what this site can link you to and because 1 of them — glucose control — matters far more to your retina than any peptide, but none of them measures your retina.
- Prediction 1 — HbA1c (Hemoglobin A1c). should be under 5.7%, because the commonest treatable cause of retinal damage is on this line, every 3 months, which matches the red-cell lifespan the test depends on. This is the prediction with real consequences. Diabetic retinopathy is among the leading causes of vision loss, prediabetes runs 5.7-6.4% and diabetes 6.5% or above, and glucose control has trial evidence for preventing progression that no peptide in this catalog approaches. Buying a retinal capsule while an HbA1c sits above 6.5% is treating the wrong end of the problem.
- Prediction 2 — Vitamin A. should sit in the 20-80 µg/dL band, 12 weeks after changing intake. This is the one blood marker with a direct, named mechanistic link to the retina: vitamin A is the precursor of the visual pigment in photoreceptors, and deficiency causes night blindness before it causes anything else. It is rare in well-fed populations and it is cheap to exclude, which is exactly why it belongs at the start rather than the end.
- Prediction 3 — Lipid Panel (Cholesterol, HDL, LDL, Triglycerides). LDL-C under 100 and triglycerides under 150 mg/dL, annually, or every 3-6 months if being treated. The retina is perfused by a small-vessel bed, and the same vascular risk factors that damage other small-vessel beds act here. This is a proxy rather than a retinal measurement, and it is on the list because it is modifiable and the retinal claim is not.
- Prediction 4 — homocysteine. 5-15 µmol/L is the reference band, 8-12 weeks after starting B vitamins. A secondary vascular marker, included so the panel is not resting on one number. It is honest to say what it is: an indirect index of a pathway associated with vascular risk, not a measurement of anything happening in your eye.
Run these before and after, not after alone. A single post-course number tells you what your body is doing, not what Visoluten did to it — and that difference is the entire point of testing.
Visoluten versus the alternatives
Visoluten versus what actually has evidence in retinal disease. For neovascular macular degeneration, drugs injected into the eye have randomized trial evidence with visual acuity as the endpoint, and they changed the natural history of a blinding condition. For diabetic retinopathy, glucose control has trial evidence for slowing progression, measured against an HbA1c where under 5.7% is normal, 5.7-6.4% is prediabetes and 6.5% or above is diabetes. For the dry form of macular degeneration, specific antioxidant and mineral formulations have been tested in large randomized trials with published effect sizes. Each of those is a real answer to a specific diagnosis, and getting the diagnosis requires someone to look at the retina.
And the comparison that is really being made when someone buys this. Not Visoluten against an injection, but Visoluten against an eye examination, which takes about 30 minutes and ends in a diagnosis. One of the two produces a diagnosis. The strongest argument against spending money here is not that the capsule is dangerous — 0 harms have been reported, because 0 of anything has been reported — it is that the alternative is so much better and so much cheaper.
What you are actually buying when you buy Visoluten
A retinal extract cannot be identity-tested. A certificate covers sterility, endotoxin, total protein and named contaminants; contents are not establishable, because a preparation defined by its process has no formula and no mass to confirm.
The source question is unusually pointed for this tissue. The retina is a thin, delicate, layered neural structure whose photoreceptor layer autolyzes within hours of death, and recovering it as a clean tissue rather than as a mixture with adjacent choroid and pigment epithelium is a dissection problem. No routine certificate reports a marker that would distinguish retina from the layers next to it. Ask the vendor which species and which tissue, and treat an unclear answer as the answer — 0 vendors in this market publish a compositional profile of any kind for an organ extract.
A certificate on a retinal extract can cover sterility, endotoxin, total protein and named contaminants and cannot establish identity. The question worth asking a vendor is which species and which tissue, because 'retina' in an abattoir context is a small, delicate, rapidly degrading structure and separating it cleanly is not trivial — and no routine certificate reports a marker that would confirm it was separated at all.
Where to get Visoluten
Buy Visoluten at BioLongevity Supplements →The evidence for Visoluten
Graded by what exists behind each claim.
Human clinical evidence
- No randomized human trials — a research compound with no commercial route to funding one, so the correlative and theoretical tiers are the evidence base rather than a consolation prize.
📊 Correlative data
- The Khavinson group reported improvements in organ-specific markers across a long series of studies from the 1980s onward. These are overwhelmingly small, single-arm, and published in Russian-language journals; independent replication outside that school is close to absent.
🧪 How the mechanism reads
- The proposal is tissue specificity: a short peptide fraction taken from one organ acts preferentially on that same organ, binding regulatory DNA sequences and shifting protein synthesis toward a younger pattern. It is a coherent mechanism and it is why these are dosed as short courses rather than continuously.
- Oral delivery is the open question, not the mechanism. Peptides are poorly absorbed intact from the gut, which is why the oral capsules run 10-20x the injectable milligram dose. Whether enough survives to reach the target tissue has not been shown in a way anyone outside the manufacturer can check.
What that tier rests on here. The tier above is class inference, and no blood tier could carry it: the retina has no blood test. Nothing is indexed under the trade name Visoluten and 0 visual acuity, visual field or retinal imaging results have been published for a retina-derived preparation.
Why an empty tier is not a verdict →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
Cell, rodent, human — and where it stops
The retina has the best-developed literature of any organ in this catalog, and none of it was run on Visoluten. It was run on Retinalamin, a retinal polypeptide preparation registered as a medicine in Russia, given by injection under the conjunctiva or into muscle in an eye clinic. Same tissue of origin, same school, different product, different route.
In cells. Khavinson 2002 reports inductive activity of retinal peptides; Khavinson 2003 reports effects on the proliferative activity of retinal and pigmented epithelial cells. Avetisov 2019 is the more pointed one — it evaluates the therapeutic sensitivity of retinal ganglion cells in culture to a targeted peptide bioregulator, which is the cell type that dies in glaucoma.
In animals, and this is the one to read carefully. Suetov 2021 used photochemical damage to rabbit retinas — a reproducible injury model with a structural read-out — and its title names the retinoprotective effect it set out to study. Its conclusion is that no significant functional or morphological evidence of a neuroprotective effect was found. The strongest animal experiment on the injectable parent of this capsule is a null result, and a reader who stopped at the title would have it backwards.
In people. Makashova 2014 in glaucomatous optic neuropathy, Khvatova 2005 in retinal abiotrophy, and Malakhova 2024 in diabetic retinopathy, the last of these using objective structural and functional monitoring rather than symptom report. All three are in Vestnik Oftalmologii, all in Russian, all single-center, and none is blinded or pre-registered as far as the record shows.
Where it stops. Visoluten is an oral capsule. Retinalamin is an injection placed next to the eye. The gap between those two is not a detail of convenience — it is the entire question of whether anything reaches the retina, and no study has ever been run on the capsule.
What nobody has tested yet
Optical coherence tomography is now routine and settles this cheaply. Malakhova 2024 already used objective structural monitoring; retinal nerve fiber layer and ganglion cell complex thickness are measured in minutes in any modern eye clinic, are reproducible to a few micrometers, and are the standard endpoint for neuroprotection trials in glaucoma. A capsule sold for eye health with no published OCT data has left the easiest experiment in ophthalmology on the table.
Nobody has compared the capsule to the injection. Two arms, one endpoint, one clinic. If the oral form does nothing, that is worth knowing before buying it; if it matches, that is a genuinely surprising result about oral peptide absorption and would be the most important finding this field has produced.
Extrapolation, labeled as such. The retina is behind a blood-retinal barrier built from the same tight junctions as the blood-brain barrier, and the one measured penetration figure in this whole class — a brain concentration of 6–8% of blood, for a different preparation — suggests that if anything crosses, very little does. The prediction that follows is unglamorous: any real oral effect should be small, slow and visible only on a structural measure over months, not on how anyone's vision feels in a week.
Sources read for this page
- Suetov AA. Retinoprotective effects of Retinalamin studied in an experimental model of photochemical damage to rabbit retinas. Vestnik Oftalmologii 2021 [Russian] · PMID 34726859
- Avetisov SE. Evaluation of therapeutic sensitivity of retinal ganglion cells to targeted peptide bioregulator in culture. Vestnik Oftalmologii 2019 [Russian] · PMID 30830079
- Malakhova AI. Objective structural and functional monitoring of polypeptide retinal neuroprotective therapy in diabetic retinopathy. Vestnik Oftalmologii 2024 [Russian] · PMID 39569781
- Makashova NV, Vasil'eva AE, Morozova NE, Ronzina IA. Application of Retinalamin for the treatment of glaucomatous optic neuropathy. Vestnik Oftalmologii 2014 [Russian] · PMID 25306728
- Khvatova AV, Khlebnikova OV, Meshkova GI, Tarasenkov AO, Shchuvatova EL, Stromova OV. Polypeptide bioregulators in the treatment of different-type abiotrophy of the retina. Vestnik Oftalmologii 2005 [Russian] · PMID 15881150
- Khavinson VKh. Inductive activity of retinal peptides. Bulletin of Experimental Biology and Medicine 2002 · PMID 12802458
- Khavinson VKh. Effects of peptides on proliferative activity of retinal and pigmented epithelial cells. Bulletin of Experimental Biology and Medicine 2003 · PMID 12937684
Visoluten — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Visoluten — safety specifics for this compound
Specific to Visoluten: 0 adverse-event data exist for any retina-derived preparation, so nothing here reports harm from the capsule. The named risk is the sharpest in this cohort, because eyes are the organ where delay is least recoverable. A sudden shower of new floaters, a flash of light, a curtain or shadow across the field, sudden painless loss of vision, or sudden distortion of straight lines are emergencies — retinal detachment and acute macular events lose vision permanently on a timescale of hours to days, and the treatments that work only work early. Nothing about a peptide capsule belongs in that sequence. The slower risk is ordinary and just as real: 3 months on a supplement while an HbA1c sits above the 6.5% diabetes threshold, or while undiagnosed glaucoma progresses, is time bought at a price nobody quotes. Any change in vision warrants an eye examination, not a second course.
Visoluten — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Visoluten moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
Visoluten — what interferes with this one specifically
The interference specific to this page is that the product competes with the interventions that actually protect vision, and the competition is for attention rather than pharmacology. The 3 modifiable drivers of retinal damage with real evidence are glucose control against an HbA1c where 5.7-6.4% is prediabetes and 6.5% or above diabetes, blood-pressure control, and smoking, which is an established risk factor for macular degeneration. A capsule taken instead of any of those is a straightforward loss. Second, a genuine pharmacological point: several medications carry retinal toxicity that is dose- and duration-dependent and is monitored with scheduled eye examinations rather than blood tests — hydroxychloroquine is the best-known example. Anyone on one of those is already in a monitoring program, and adding an unstudied product with 0 published ocular results does not change what that program is watching for, but it does add a variable to any change they find.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Visoluten in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Visoluten
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Visoluten — frequently asked questions
Is Visoluten a peptide or an extract?
An extract — a peptide complex from retina, not a single defined molecule. That is why a certificate of analysis cannot confirm its identity the way it can for a synthetic peptide.
Is there a human trial of Visoluten?
Nothing is indexed under the trade name Visoluten. No visual acuity, visual field or retinal imaging endpoint has been published for a retina-derived peptide preparation — which matters, because those are the only endpoints that could settle it and none of them is a blood test.
What should I measure if I run Visoluten?
Before and after, not after alone. The falsifiability section on this page names the specific markers, the direction each should move and the timescale — and says what a null result would rule out.
References & further reading
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR — Peptide Regulation of Gene Expression: A Systematic Review · Molecules 2021;26(22):7053 · PMID 34834147
- Khavinson V, Linkova N, Kozhevnikova E, Trofimova S — EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease · Molecules 2021;26(1):159 · PMID 33396470
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group) — The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis · Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
What Visoluten is used for
Visoluten appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.